000			04400nam a22004335i 4500
999			_c368689 _d368689 _x1
001			368689
003			ES-MaUEC
005			20230102121758.0
006			a||||fo|||| 00| 0
007			cr nn nnnaamaa
008			220103s2022 sz | s |||| 0|eng d
020			_a9783030805463
024	7		_a10.1007/978-3-030-80546-3 _2doi
040			_aES-MaUEC _bspa _cES-MaUEC _dES-MaUEC
050		4	_aRC280 .G4 _b2022 EB
245	1	0	_aNeoadjuvant Immunotherapy Treatment of Localized Genitourinary Cancers : _bMultidisciplinary Management _cedited by Andrea Necchi, Philippe E. Spiess
250			_aFirst edition 2022
264		1	_aCham _bSpringer International Publishing, _c2022
300			_a1 recurso en línea (XVIII, 315 páginas) _b29 ilustraciones, 26 ilustraciones a color
336			_2rdacontent _aTexto _btxt
337			_2rdamedia _aelectrónico _bc
338			_2rdacarrier _arecurso electrónico _bcr
347			_aarchivo de texto _bPDF
505	0		_aIntroduction -- State-of-the art and ongoing developments -- Clinical cases debate: neoadjuvant checkpoint inhibition vs standard chemotherapy -- Slideshow of tumor samples before and after checkpoint inhibition -- Ongoing trials and clinical trials endpoints debate: the role of pathological response as a surrogate of survival endpoints -- State-of-the-art and future role of molecular biomarkers for patient selection -- Background of immunotherapy trials in prostate cancer -- Clinical case debate: immunotherapy vs alternative therapies in the neoadjuvant and adjuvant setting of localized, high-risk prostate cancer -- Cytoreductive nephrectomy in the era of targeted therapy and immunotherapy -- Clinical cases debate: Neoadjuvant vs adjuvant immunotherapy in localized RCC -- Benchmark of surgical safety results -- What the scientific data tell us about predictive biomarkers of immunotherapy efficacy across the GU malignancies -- Clinical cases debate: biomarker-driven patient selection vs unselective perioperative strategies. .
520			_aThis book aims to provide readers with a current overview of enrolling trials with immune-checkpoint inhibitors in the preoperative setting of localized bladder cancer, renal cell carcinoma, and prostate cancer. The advent of immunotherapy has revolutionized treatments of genitourinary malignancy and evolved strategies for multidisciplinary management. This book explains neoadjuvant checkpoint inhibitors in localized genitourinary cancers, providing insights into the mechanisms of response and development of resistance of cancer cells to immunotherapy. It debates optimal trial design of preoperative checkpoint inhibitors in GU tumors, including optimal endpoints and the role of pathologic response as a surrogate endpoint of survival. It also illuminates clinical management of patients with organ-confined GU tumors, such as side effect management and perioperative safety, before providing an overview of biomarker use for patient selection across the early-stage GU malignancies. Lastly, the book provides the reader with the most up-to-date data emerging from clinical trials involving immunotherapy in early-stage GU malignancies. Neoadjuvant Immunotherapy Treatment of Localized Genitourinary Cancers: Multidisciplinary Management provides a comprehensive review of the field, serving as a valuable resource for urologists, medical oncologists, pathologists, fellows in urologic oncology, upper-level residents training in urology and medical oncology, as well as pharmacists interested in RCC clinicians.
988			_aSpringer_Medicine_2022
650		7	_2embne _9172317 _aAparato genital femenino _xCáncer
650		7	_2embne _9138564 _aAparato genital masculino _xCancer
700	1		_aNecchi, Andrea _eeditor literario _4edt _4http://id.loc.gov/vocabulary/relators/edt
700	1		_aSpiess, Philippe E. _eeditor literario _4edt _4http://id.loc.gov/vocabulary/relators/edt
776	0	8	_iPrinted edition: _z9783030805456
776	0	8	_iPrinted edition: _z9783030805470
776	0	8	_iPrinted edition: _z9783030805487
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://doi.org/10.1007/978-3-030-80546-3 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
942			_2lcc _cLE _n0
998			_b04/2022 _dz _eh _zSI